How Much Does Medical Equipment Actually Cost?

Medical equipment costs range from a few thousand dollars for a handheld ultrasound probe to several million for a single MRI scanner, and the purchase price is usually the smallest part of the total bill. Installation, service contracts, training, sterilization, regulatory compliance, and eventual disposal can double or triple what a hospital actually spends over a device’s lifetime. Understanding those layers explains why healthcare costs are so stubbornly high and why two hospitals buying the same machine can end up paying wildly different amounts.

What the Big Machines Cost Up Front

The equipment that dominates hospital budgets falls into a handful of categories: imaging systems (MRI, CT, X-ray), radiation therapy machines, surgical robots, and laboratory analyzers. A standard 1.5-tesla MRI scanner is commonly cited in the range of one to three million dollars, but the sticker price shifts depending on the field strength, the manufacturer, and the accessories bundled in. Newer low-field MRI systems running at 0.55 tesla can cut the purchase price by roughly 40 to 50 percent compared to a 1.5-tesla unit, while also reducing installation costs by up to 70 percent because the lighter, smaller magnet can be moved into a building without tearing open an exterior wall or installing a quench pipe.¹ Those installation savings are easy to overlook. Reinforced flooring, electromagnetic shielding, dedicated cooling systems, and building modifications for a conventional MRI can add hundreds of thousands of dollars on top of the machine itself.

CT scanners, linear accelerators for radiation therapy, and catheterization lab equipment sit in a similar bracket, generally running from several hundred thousand dollars to well over two million depending on capability. At the extreme end, proton therapy systems for cancer treatment can cost upwards of a hundred million dollars to build out, though only a small number of centers worldwide operate them. For most hospitals, the practical ceiling is the MRI or CT suite, and the real financial question is not what the scanner costs to buy but what it costs to own.

The Surprisingly Affordable End of the Spectrum

Not all medical equipment demands a capital campaign. Handheld ultrasound devices have dropped dramatically in price over the past decade, and a 2024 comparison of six widely used models found probe costs ranging from about $2,700 to $8,000, excluding the tablet used to display images.² Some of those prices include annual subscription fees of a few hundred dollars for cloud storage or software updates. For perspective, a full-sized cart-based ultrasound system used in radiology departments still runs $20,000 to $200,000 depending on the transducers and software packages, so the handheld market represents a genuine cost disruption. Emergency physicians, rural clinics, and ambulance services that could never justify a cart-based unit can now put imaging capability in a coat pocket.

Durable medical equipment used outside hospitals, such as wheelchairs, hospital beds, oxygen concentrators, and CPAP machines, occupies yet another price tier. Medicare’s competitive bidding program, which sets reimbursement rates for these items, has pushed supplier prices down to levels comparable to what large commercial insurers negotiate.³ That means the price a patient or insurer pays for a home oxygen setup or power wheelchair is at least somewhat anchored by competitive market pressure, unlike many hospital-based devices where a single manufacturer may dominate.

Maintenance and Service Contracts

The ongoing cost of keeping equipment running often rivals the purchase price over a typical seven-to-ten-year ownership cycle. Hospitals sign service contracts with manufacturers or third-party providers, and the structure of those contracts matters more than most administrators realize. A comparative analysis of service contract types found that the choice between a full-service plan, a shared-service plan, and a parts-only plan has significant financial and operational consequences, with internal maintenance capabilities and manufacturer support being key factors in which model actually saves money.⁴

Counterintuitively, the most comprehensive service plans are not always the cheapest. Research on maintenance service contracts found that switching from a basic pay-per-service arrangement to a fixed-fee, full-protection plan actually reduced equipment reliability and increased service costs.⁵ The reason comes down to incentives: when the hospital bears the financial risk of a breakdown, staff tend to operate the equipment more carefully, and service technicians have less motivation to log unnecessary visits. Under a fixed-fee contract, both sides behave differently. Operators are less cautious because repairs are “free,” and service providers may be less aggressive about preventive measures because they absorb the cost of every call. A hospital paying per incident ends up with fewer incidents.

For the low-field MRI systems mentioned earlier, maintenance costs run about 45 percent less than comparable contracts on 1.5-tesla machines, largely because the simpler magnet technology requires less helium cooling and fewer specialized parts.¹ That kind of savings compounds over a decade of ownership and is a major reason why some facilities are reconsidering whether they need the highest-end hardware for every clinical task.

Single-Use Versus Reusable Instruments

One of the less obvious cost questions in healthcare involves surgical instruments and procedural devices that are either designed for single use or reprocessed and sterilized between patients. The intuitive assumption is that reusable equipment should be cheaper over time, since you buy it once and keep using it. The reality is messier. Sterilization is labor-intensive and expensive, and those costs can flip the equation.

A cost analysis of endoscopic carpal tunnel release procedures found that disposable equipment totaled about $917 per case while reusable equipment came to $1,019, making the single-use option roughly $100 cheaper.⁶ The reusable option became cheaper only when the price of disposable components exceeded specific thresholds or when setup times for reusable trays dropped below about seven minutes. In spinal fusion surgery, a similar pattern emerged: mean processing time for single-use devices was about 33 minutes compared to 176 minutes for reusable ones, and the sterilization and recomposing steps drove a cost difference of roughly €181 per procedure in favor of single-use.⁷

These numbers do not mean single-use is universally cheaper. A hospital that performs hundreds of the same procedure per year and has an efficient sterilization department can sometimes make reusable instruments pencil out. The break-even point depends on procedure volume, local labor costs, and the price of the disposable alternative. But the broader point is that “just reuse it” is not the automatic money-saver people assume, because the hidden infrastructure of sterilization, storage, tracking, and quality control adds up fast.

Buying Versus Leasing

Hospitals and research facilities face a familiar dilemma when acquiring expensive equipment: pay the full capital cost up front, or spread payments over time through a lease. Leasing has become an increasingly attractive option for high-technology devices that risk becoming obsolete within a few years. An analysis of scientific instrument procurement for academic core facilities concluded that leasing offers predictable, consistent costs and helps institutions stay technologically current without large upfront outlays.⁸

For radiotherapy equipment specifically, the trade-offs have been studied in detail. Leasing allows acquisition within tighter budget and cash-flow constraints and protects against obsolescence, which matters when treatment technology evolves rapidly. The downsides are that the institution never owns the equipment, the total revenue cost over the lease term can exceed the purchase price, and lease conditions sometimes restrict how the equipment can be used or modified.⁹ In practice, many hospitals use a mix: they purchase stable, long-lifecycle equipment like surgical tables and autoclaves, and lease rapidly evolving technology like imaging systems and robotic platforms.

How Hospitals Negotiate Lower Prices

Few hospitals buy equipment at list price. Most belong to group purchasing organizations, or GPOs, which pool the buying power of hundreds or thousands of facilities to negotiate volume discounts. These alliances have been shown to reduce costs by lowering product prices, cutting transaction costs through standardized contracts, and generating revenue through rebates and dividends.¹⁰ The savings are clearest for commodity items and pharmaceuticals, where products are interchangeable and competition among suppliers is fierce. For specialized equipment with fewer manufacturers, the leverage is smaller.

GPOs are not without controversy. They typically charge contract administration fees to manufacturers, which critics argue could inflate prices or distort the supply chain. Research into these fees found that while they affect how profits are distributed between manufacturers and the purchasing organizations themselves, they do not appear to change the total purchasing costs that hospitals ultimately pay.¹¹ In other words, the middleman takes a cut, but it comes out of the manufacturer’s margin rather than being added to the hospital’s bill. Whether that arrangement stifles innovation by squeezing smaller suppliers is a separate and unresolved debate.

The Refurbished Market

A growing number of third-party companies sterilize, refurbish, and remanufacture medical devices, then resell them to hospitals at a fraction of the original price.¹² This market is particularly active for imaging equipment, where a refurbished CT scanner or ultrasound system can cost 30 to 60 percent less than a new one. The trade-off is risk: refurbished devices may have higher failure probabilities depending on age, previous use, and the quality of the remanufacturing process. Hospitals evaluating refurbished equipment weigh the device cost against the probability and cost of failure, and for many routine applications the math favors the used machine.

Regulatory oversight of refurbished equipment varies by country. In the United States, devices reprocessed by a registered third party must meet FDA standards, but enforcement and inspection frequency are ongoing concerns. For budget-constrained facilities, especially in lower-income settings, refurbished imaging and laboratory equipment often represents the only realistic path to offering certain diagnostic services at all.

Why the Same Device Costs Far More in the United States

Perhaps the most striking aspect of medical equipment pricing is how much it varies between countries. A study comparing prices for cardiac implant devices found that the United States paid two to six times more than Germany, which generally had the lowest prices in Europe.¹³ Prices for coronary stents and pacemakers were also higher in France and Italy than in the United Kingdom, where prices were closer to Germany’s. These are not different products: the same stent made by the same manufacturer, implanted for the same clinical reason, simply carries a different price tag depending on where the hospital is located.

The reasons are structural. Many European countries use centralized price negotiations, reference pricing systems, or national procurement bodies that set maximum reimbursement rates. The United States relies more heavily on individual hospital-level or GPO-level negotiation, which produces wider price variation and, on average, higher prices. Manufacturer market power also plays a role: when only two or three companies make a particular implant, the negotiating leverage shifts away from the buyer. This price gap is not limited to implants. Studies of imaging equipment, surgical supplies, and even hospital beds have found similar patterns, though the magnitude varies by product category.

Regulatory Costs Baked Into the Price

Every medical device sold legally has already absorbed the cost of regulatory clearance or approval. For low-risk devices like bandages and tongue depressors, that overhead is minimal. For high-risk implants and complex machines, the cost of clinical trials, documentation, quality management systems, and regulatory submissions adds substantially to the final price. Research modeling the financial impact of different regulatory pathways found that the stringency of the approval process directly affects both the cost to manufacturers and the price passed on to hospitals and insurers.¹⁴ A process resembling drug-style regulation, with large randomized trials required before market entry, would raise device prices significantly but could also prevent the adoption of devices that turn out not to work. The current system strikes a compromise, allowing faster market entry with post-market surveillance intended to catch problems after the fact.

This trade-off is worth understanding because it explains part of the price gap between a relatively simple device that can reach market through a streamlined pathway and a novel implant that requires years of clinical data. Hospitals absorb those development costs indirectly every time they purchase a device, and the cost is invisible to patients who see only the final bill.

What Happens When Equipment Is Retired

The cost story does not end when a machine stops being useful. Decommissioning medical equipment involves disposal logistics, environmental compliance, and decisions about whether to donate, resell, recycle, or simply discard. A study of retired hemodialysis machines across Dutch hospitals identified five distinct strategies: outright disposal, used by about 39 percent of centers; donation, used by about 23 percent; resale, also about 23 percent; reuse within the organization at about 8 percent; and recycling or trade-in at about 8 percent.¹⁵ Each path carries its own financial implications, including repair costs needed to make a machine suitable for donation, depreciation write-offs, potential resale revenue, and shipping expenses. Environmental consequences were recognized by most centers but rarely formalized into policy, meaning sustainability was more of an afterthought than a planned part of the equipment lifecycle.

For imaging equipment containing radioactive sources, such as older gamma cameras, decommissioning involves additional regulatory steps and licensed waste handling that can cost tens of thousands of dollars. Even for equipment without hazardous materials, data security is a growing concern: modern devices store patient information, and wiping that data before disposal or resale is both a legal requirement and a practical cost.

The Equipment Arms Race and What It Means for Patients

Hospitals do not always buy equipment because they need it. Competition for patients and physician referrals drives an equipment arms race, particularly in systems where revenue is tied to the volume of procedures performed. Research on Chinese hospitals found that a one percent increase in total equipment value was associated with a 0.12 percent increase in inpatient service volume and a 0.21 percent increase in outpatient volume, but had no measurable effect on the size of individual patient bills.¹⁶ In other words, hospitals that invested more in equipment attracted more patients but did not charge each patient more. The equipment served as a marketing tool as much as a clinical one.

This dynamic has real consequences for healthcare spending. When neighboring hospitals each purchase their own MRI suite to stay competitive, the region ends up with more scanners than it needs. Each scanner must generate enough revenue to justify its existence, which can lead to overuse: ordering imaging studies that are clinically marginal because the machine needs to be kept busy. Health planners in several countries have tried to address this through certificate-of-need programs that require hospitals to demonstrate demand before acquiring expensive technology, with mixed results. The tension between access, competition, and cost control remains one of the unsolved problems in healthcare finance.

Emergency Stockpiles and Surge Equipment

The COVID-19 pandemic highlighted another hidden cost: maintaining stockpiles of equipment for emergencies. Ventilators, patient monitors, and personal protective equipment need to be stored, inspected, and periodically replaced even when they sit unused for years. A review of healthcare stockpile practices found that managing local or regional caches requires sustained investment in infrastructure and training to ensure the integrity of stored supplies and enable rapid deployment during mass casualty events.¹⁷ Without that investment, stockpiled equipment degrades. Batteries die, sterile packaging expires, software becomes outdated, and when the emergency arrives, the equipment may not work. The cost of maintaining a stockpile is ongoing and invisible to the public until the moment it is needed, at which point the cost of not maintaining it becomes painfully visible instead.